valacyclovir and Alzheimer-Disease

valacyclovir has been researched along with Alzheimer-Disease* in 3 studies

Trials

1 trial(s) available for valacyclovir and Alzheimer-Disease

ArticleYear
Antiviral therapy: Valacyclovir Treatment of Alzheimer's Disease (VALAD) Trial: protocol for a randomised, double-blind,placebo-controlled, treatment trial.
    BMJ open, 2020, 02-06, Volume: 10, Issue:2

    After infection, herpes simplex virus-1 (HSV1) becomes latent in the trigeminal ganglion and can enter the brain via retrograde axonal transport. Recurrent reactivation of HSV1 may lead to neurodegeneration and Alzheimer's disease (AD) pathology. HSV1 (oral herpes) and HSV2 (genital herpes) can trigger amyloid beta-protein (Aβ) aggregation and HSV1 DNA is common in amyloid plaques. Anti-HSV drugs reduce Aβ and phosphorylated tau accumulation in cell-culture models. Cognitive impairment is greater in patients with HSV seropositive, and antiviral drugs show robust efficacy against peripheral HSV infection. Recent studies of electronic health records databases demonstrate that HSV infections increase dementia risk, and that antiviral medication treatment reduces this risk. The generic antiviral drug valacyclovir was superior to placebo in improving memory in a schizophrenia pilot trial but has not been tested in AD.. In patients with mild AD who test positive for HSV1 or HSV2 serum antibodies, valacyclovir, repurposed as an anti-AD drug, will be compared with placebo (lactose pills) in 130 patients (65 valacyclovir and 65 placebo) in a randomised, double-blind, 78-week phase II proof-of-concept trial. Patients on valacyclovir, dose-titrated from 2 g to a targeted oral dose of 4 g daily, compared with placebo, are hypothesised to show smaller cognitive and functional decline, and, using. The trial is being overseen by the New York State Psychiatric Institute Institutional Review Board (protocol 7537), the National Institute on Ageing, and the Data Safety Monitoring Board. Written informed consent is obtained for all subjects. Results will be disseminated via publication, clinicaltrials.gov, media and conferences.. ClinicalTrials.gov identifier (NCT03282916) Pre-results.

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Antiviral Agents; Cognitive Dysfunction; Double-Blind Method; Female; Herpes Simplex; Herpesvirus 1, Human; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; tau Proteins; Valacyclovir; Virus Replication

2020

Other Studies

2 other study(ies) available for valacyclovir and Alzheimer-Disease

ArticleYear
Insights of Valacyclovir in Treatment of Alzheimer's Disease: Computational Docking Studies and Scopolamine Rat Model.
    Current neurovascular research, 2022, Volume: 19, Issue:3

    Alzheimer's Disease (AD) impairs memory and cognitive functions in the geriatric population and is characterized by intracellular deposition of neurofibrillary tangles, extracellular deposition of amyloid plaques, and neuronal degeneration. Literature suggests that latent viral infections in the brain act as prions and promote neurodegeneration. Memantine possesses both anti-viral and N-methyl-D-aspartate (NMDA) receptor antagonistic activity.. This research was designed to evaluate the efficacy of antiviral agents, especially valacyclovir, a prodrug of acyclovir in ameliorating the pathology of AD based on the presumption that anti-viral agents targeting the Herpes Simplex Virus (HSV) can have a protective effect on neurodegenerative diseases like Alzheimer's disease.. Thus, we evaluated acyclovir's potential activity by in-silico computational docking studies against acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), and beta-secretase 1 (BACE-1). These findings were further evaluated by in-vivo scopolamine-induced cognitive impairment in rats. Two doses of valacyclovir, a prodrug of acyclovir (100 mg/kg and 150 mg/kg orally) were tested.. Genetic Optimisation for Ligand Docking scores and fitness scores of acyclovir were comparable to donepezil. Valacyclovir improved neurobehavioral markers. It inhibited AChE and BuChE (p<0.001) enzymes. It also possessed disease-modifying efficacy as it decreased the levels of BACE-1 (p<0.001), amyloid beta 1-42 (p<0.001), amyloid beta 1-40 (p<0.001), phosphorylatedtau (p<0.001), neprilysin (p<0.01), and insulin-degrading enzyme. It ameliorated neuroinflammation through decreased levels of tumour necrosis factor α (p<0.001), nuclear factor-kappa B (p<0.001), interleukin 6 (p<0.001), interleukin 1 beta (p<0.001), and interferon-gamma (p<0.001). It also maintained synaptic plasticity and consolidated memory. Histopathology showed that valacyclovir could restore cellular density and also preserve the dentate gyrus.. Valacyclovir showed comparable activity to donepezil and thus can be further researched for the treatment of Alzheimer's disease.

    Topics: Acetylcholinesterase; Acyclovir; Aged; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antiviral Agents; Butyrylcholinesterase; Donepezil; Humans; Prodrugs; Rats; Scopolamine; Valacyclovir

2022
Are infections seeding some cases of Alzheimer's disease?
    Nature, 2020, Volume: 587, Issue:7832

    Topics: Adult; Alzheimer Disease; Amyloid beta-Peptides; Animals; Borrelia burgdorferi; Chlamydophila pneumoniae; Genetic Predisposition to Disease; Glymphatic System; Humans; Immunity, Innate; Inflammation; Membrane Proteins; Mice; Middle Aged; Models, Biological; Organoids; Plaque, Amyloid; Pore Forming Cytotoxic Proteins; Porphyromonas gingivalis; RNA-Binding Proteins; Simplexvirus; tau Proteins; Tauopathies; Valacyclovir

2020